CVS stock price today has held its ground despite fluctuations in the S&P 500 healthcare index, signaling strong relative strength compared to peers like Walgreens and Rite Aid. The previous big move we wrote about was 6 days ago when the stock dropped 2.9% on the news that the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs. The probe, conducted under Section 232 of the Trade Expansion Act, examines whether imports of items like syringes, infusion pumps, and surgical instruments pose a national security risk. Such investigations can pave the way for new import duties, creating a significant overhang for the sector. The goal of potential tariffs would be to boost domestic manufacturing by increasing the cost of foreign goods. This development has introduced new uncertainty for the industry, leading to broad-based declines in the stocks of major manufacturers, including Baxter International and GE HealthCare, as investors weigh the potential impact on supply chains and costs. Want to take a deep dive into Cramer's world? Hit him up! Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram Trading volumes for CVS stock price today are slightly above the 30-day average, a sign that institutional investors may be repositioning ahead of potential drug pricing legislation updates.